Literature DB >> 34436751

Repeatability of image features extracted from FET PET in application to post-surgical glioblastoma assessment.

Nathaniel Barry1, Pejman Rowshanfarzad2, Roslyn J Francis3,4, Anna K Nowak3,5, Martin A Ebert2,6,7.   

Abstract

Positron emission tomography (PET) imaging using the amino acid tracer O-[2-(18F)fluoroethyl]-L-tyrosine (FET) has gained increased popularity within the past decade in the management of glioblastoma (GBM). Radiomics features extracted from FET PET images may be sensitive to variations when imaging at multiple time points. It is therefore necessary to assess feature robustness to test-retest imaging. Eight patients with histologically confirmed GBM that had undergone post-surgical test-retest FET PET imaging were recruited. In total, 1578 radiomic features were extracted from biological tumour volumes (BTVs) delineated using a semi-automatic contouring method. Feature repeatability was assessed using the intraclass correlation coefficient (ICC). The effect of both bin width and filter choice on feature repeatability was also investigated. 59/106 (55.7%) features from the original image and 843/1472 (57.3%) features from filtered images had an ICC ≥ 0.85. Shape and first order features were most stable. Choice of bin width showed minimal impact on features defined as stable. The Laplacian of Gaussian (LoG, σ = 5 mm) and Wavelet filters (HLL and LHL) significantly improved feature repeatability (p ≪ 0.0001, p = 0.003, p = 0.002, respectively). Correlation of textural features with tumour volume was reported for transparency. FET PET radiomic features extracted from post-surgical images of GBM patients that are robust to test-retest imaging were identified. An investigation with a larger dataset is warranted to validate the findings in this study.
© 2021. Australasian College of Physical Scientists and Engineers in Medicine.

Entities:  

Keywords:  FET PET; Glioblastoma; Radiomics; Repeatability

Mesh:

Substances:

Year:  2021        PMID: 34436751     DOI: 10.1007/s13246-021-01049-4

Source DB:  PubMed          Journal:  Phys Eng Sci Med        ISSN: 2662-4729


  55 in total

Review 1.  O-(2-[18F]fluoroethyl)-L-tyrosine: uptake mechanisms and clinical applications.

Authors:  Karl-Josef Langen; Kurt Hamacher; Matthias Weckesser; Frank Floeth; Gabriele Stoffels; Dagmar Bauer; Heinz H Coenen; Dirk Pauleit
Journal:  Nucl Med Biol       Date:  2006-04       Impact factor: 2.408

2.  Amino acid PET in neuro-oncology: applications in the clinic.

Authors:  Norbert Galldiks; Karl-Josef Langen
Journal:  Expert Rev Anticancer Ther       Date:  2017-03-11       Impact factor: 4.512

Review 3.  Advanced magnetic resonance imaging in glioblastoma: a review.

Authors:  Gaurav Shukla; Gregory S Alexander; Spyridon Bakas; Rahul Nikam; Kiran Talekar; Joshua D Palmer; Wenyin Shi
Journal:  Chin Clin Oncol       Date:  2017-08

4.  O-(2-[18F]fluorethyl)-L-tyrosine PET in the clinical evaluation of primary brain tumours.

Authors:  M Weckesser; K J Langen; C H Rickert; S Kloska; R Straeter; K Hamacher; G Kurlemann; H Wassmann; H H Coenen; O Schober
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-01-14       Impact factor: 9.236

5.  Diagnostic performance of 18F-FET PET in newly diagnosed cerebral lesions suggestive of glioma.

Authors:  Marion Rapp; Alexander Heinzel; Norbert Galldiks; Gabriele Stoffels; Jörg Felsberg; Christian Ewelt; Michael Sabel; Hans J Steiger; Guido Reifenberger; Thomas Beez; Heinz H Coenen; Frank W Floeth; Karl-Josef Langen
Journal:  J Nucl Med       Date:  2012-12-11       Impact factor: 10.057

6.  Static and dynamic 18F-FET PET for the characterization of gliomas defined by IDH and 1p/19q status.

Authors:  Antoine Verger; Gabriele Stoffels; Elena K Bauer; Philipp Lohmann; Tobias Blau; Gereon R Fink; Bernd Neumaier; Nadim J Shah; Karl-Josef Langen; Norbert Galldiks
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-10-17       Impact factor: 9.236

7.  Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.

Authors:  Roger Stupp; Warren P Mason; Martin J van den Bent; Michael Weller; Barbara Fisher; Martin J B Taphoorn; Karl Belanger; Alba A Brandes; Christine Marosi; Ulrich Bogdahn; Jürgen Curschmann; Robert C Janzer; Samuel K Ludwin; Thierry Gorlia; Anouk Allgeier; Denis Lacombe; J Gregory Cairncross; Elizabeth Eisenhauer; René O Mirimanoff
Journal:  N Engl J Med       Date:  2005-03-10       Impact factor: 91.245

8.  Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.

Authors:  Roger Stupp; Monika E Hegi; Warren P Mason; Martin J van den Bent; Martin J B Taphoorn; Robert C Janzer; Samuel K Ludwin; Anouk Allgeier; Barbara Fisher; Karl Belanger; Peter Hau; Alba A Brandes; Johanna Gijtenbeek; Christine Marosi; Charles J Vecht; Karima Mokhtari; Pieter Wesseling; Salvador Villa; Elizabeth Eisenhauer; Thierry Gorlia; Michael Weller; Denis Lacombe; J Gregory Cairncross; René-Olivier Mirimanoff
Journal:  Lancet Oncol       Date:  2009-03-09       Impact factor: 41.316

Review 9.  Advanced imaging techniques for neuro-oncologic tumor diagnosis, with an emphasis on PET-MRI imaging of malignant brain tumors.

Authors:  Wynton B Overcast; Korbin M Davis; Chang Y Ho; Gary D Hutchins; Mark A Green; Brian D Graner; Michael C Veronesi
Journal:  Curr Oncol Rep       Date:  2021-02-18       Impact factor: 5.075

10.  Voxel-wise analysis of dynamic 18F-FET PET: a novel approach for non-invasive glioma characterisation.

Authors:  Lena Vomacka; Marcus Unterrainer; Adrien Holzgreve; Erik Mille; Astrid Gosewisch; Julia Brosch; Sibylle Ziegler; Bogdana Suchorska; Friedrich-Wilhelm Kreth; Jörg-Christian Tonn; Peter Bartenstein; Nathalie Lisa Albert; Guido Böning
Journal:  EJNMMI Res       Date:  2018-09-10       Impact factor: 3.138

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.